GE Healthcare Technologies Inc
Health Care
GE Healthcare Technologies Inc (GEHC) Stock News
The latest GEHC headlines and market coverage — 5 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz is investigating GE HealthCare Technologies for potential federal securities law violations. The investigation follows the company's April 2026 earnings report, which revealed a PDx supplier recall that impacted profit performance and margins, leading to reduced full-year EPS guidance and a 13.2% stock price decline. The company's CFO also stepped down in July 2026.
- Zacks Investment Research·
GE HealthCare (GEHC) Upgraded to Buy: Here's Why
GE HealthCare Technologies (GEHC) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company is expected to earn $4.93 per share for fiscal year 2026, with analysts steadily raising estimates over the past three months. The upgrade positions GEHC in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals.
- Zacks Investment Research·
GEHC or SYK: Which Is the Better Value Stock Right Now?
In a comparison of two Medical-Products sector stocks, GE HealthCare Technologies (GEHC) emerges as the superior value option for value investors. GEHC has a Zacks Rank of #2 (Buy) with improving earnings outlook, a lower forward P/E of 12.98 versus Stryker's 18.76, and a Value grade of A compared to Stryker's C grade. Key valuation metrics favor GEHC, including a lower PEG ratio (1.69 vs 1.76) and P/B ratio (2.63 vs 4.5).
- Zacks Investment Research·
GEHC vs. HAE: Which Stock Is the Better Value Option?
In a comparison of two medical products stocks, GE HealthCare Technologies (GEHC) emerges as the more attractive value investment option compared to Haemonetics (HAE). GEHC holds a Zacks Rank #2 (Buy) with a Value grade of B, featuring a lower forward P/E ratio of 14.54 and P/B ratio of 2.95. HAE, ranked #3 (Hold) with a Value grade of C, has a higher forward P/E of 19.67 and P/B of 5.64, suggesting GEHC offers better value metrics and a more improving earnings outlook.
- GlobeNewswire Inc.·
GEHC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving GE HealthCare Technologies Inc.
GE HealthCare reported Q1 2026 earnings that missed consensus estimates and cut full-year guidance due to a PDx supplier issue. The stock declined 13% following the announcement. Law firm Kirby McInerney LLP is investigating potential securities law violations by the company and its senior management.